Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Journal of Neurology|January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE studyPiero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
Epilepsy Research|November 4, 2008
High prevalence of epilepsy in a village in the Littoral Province of CameroonFrancesca Prischich, Marta De Rinaldis, Flaminia Bruno, et al.
European Journal of Neurology|September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT studyFabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology|November 16, 2007
Familial mesial temporal lobe epilepsy (FMTLE) : a clinical and genetic study of 15 Italian familiesPasquale Striano, Antonio Gambardella, Antonietta Coppola, et al.
The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Epilepsy Research|April 29, 2008
Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteinsErica Diani, Carlo Di Bonaventura, Oriano Mecarelli, et al.
Epilepsy Research and Treatment|September 1, 2012
ADAM23, a Gene Related to LGI1, Is Not Linked to Autosomal Dominant Lateral Temporal EpilepsyLaura Rigon, Andrea Vettori, Giorgia Busolin, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Pageof 8